iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

Recruiting now · Early Phase 1

Conditions studied: Huntington Disease, HD, PET Tracer, Positron Emission Tomography, Radioligand, Imaging, mHTT, Huntington's, Huntington's Disease

In brief

This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand \[11C\]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD). The study is divided into three cohorts defined by the Huntington's Disease Integrated Staging System (HD-ISS): Cohort 1 - initial tracer validation (3 healthy controls (HCs)); Cohort 2 - target validation and test-retest variability (6 HD-ISS Stage 3 participants and 6 age and biological sex-matched HCs); Cohort 3 - target sensitivity (6 HD-ISS Stage 2 participants and 6 age and biological sex-matched HCs). An interim analysis (IA) will be conducted after the completion of each cohort, followed by a final analysis for the study. In addition to imaging, exploratory biomarkers, including somatic instability index, soluble mHTT and total huntingtin (HTT), will be assessed. All participants with HD (PwHD) will have an additional blood sample drawn at the screening visit to assess the somatic instability index and will also be invited to provide an optional cerebrospinal fluid (CSF) sample for measurement of soluble mHTT and total HTT.

Key facts

Study ID

NCT06634628

Run by

CHDI Foundation, Inc.

People needed

27

Starts

2026-02-24

Expected to finish

2028-03-01

Last updated by the study team

2026-03-13

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• PwHD HD-ISS Stages 2 and 3 and HC participants who:
• Are female or male adults, age 18-64 years old, inclusive.
• Have body mass index (BMI) between 19 and 35, inclusive.
• Have capacity to give full informed consent in writing and have read and signed the informed consent form (ICF).
• Are able to comply with study procedures, including fasting and blood sampling.
• Are able and willing to travel to the imaging center in Leuven, Belgium.
• Are willing to comply with the use of adequate contraceptive measures.
• HD-ISS Stage 2 participants who:
• Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and
• Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.
• Have a PIN score of 0.47 to 1.84 [prognostic index normed for HD (PIN) where PIN = (PIHD - 883)/1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)].
• HD-ISS Stage 2 participants who:
• Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and 8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.
• Have a PIN score of 0.47 to 1.84 [prognostic index normed for HD (PIN) where PIN = (PIHD - 883)/1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)].
• HC participants who:
• Have no known family history of HD; or 14. Have a known family history of HD and have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG < 36).
• Age match (+/- 5 years) and biological sex match to each HD participant in Cohort 2 and Cohort 3 (except for Cohort 1, no matching).

You may not qualify if…

• PwHD HD-ISS Stages 2 and 3 and HC participants who:
• Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.
• Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.
• Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.
• Are pregnant and breastfeeding females.
• Have concomitant use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid).
• Have a bleeding disorder.
• Have a needle phobia.
• Have any metal objects present in the body that are incompatible with MRI.
• Have metal objects present in the body that are compatible with MRI and are located in the head or neck.
• Have any clinically significant results on safety laboratory tests that, in the opinion of the Investigator, would either put the participant at risk or interfere with the conduct of the study or interpretation of data. These tests include, but are not limited to:
• a. positive results for HBsAg, HepC, HIV-1 or HIV-2 (will also be reported as required by local/national regulations),
• b. clinically significant, abnormal results for safety laboratory tests.
• PwHD participants who:
• If they are using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.
• HC participants who:
• Have a family history of HD and have not been tested for the huntingtin gene (CAG) expansion.

Where it is running

• Universitaire Ziekenhuizen Leuven/ UZ Leuven/ UZL — Leuven, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.